Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 36800 clinical trials
Carbon-Fibre Accessory (CARA) for Supine Breast Positioning to Reduce Toxicity in Whole Breast Radiotherapy

This trial is designed to assess the efficacy of a novel carbon-fibre adjustable reusable accessory (CARA) for breast support to reduce skin toxicity and unwanted normal tissue dose in comparison to the current clinical standard for supine breast support during whole breast RT.

  • 0 views
  • 16 Feb, 2024
  • 1 location
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.

This is a Phase II, open-label, randomized controlled umbrella trial evaluating the efficacy and safety of multiple targeted treatment in patients with metastaticTNBC.

stage iv breast cancer
everolimus
triple-negative breast cancer
capecitabine
targeted therapy
  • 0 views
  • 16 Feb, 2024
  • 1 location
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC neoSCORE

This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.

platelet count
granulocyte colony stimulating factor
blood pregnancy test
cancer
myocardial infarction
  • 0 views
  • 05 Aug, 2020
A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma

The worldwide collaboration is referred to as GLOBAL BALLAD and consists of a number of individual parallel prospective studies addressing the same objectives with similar designs brought together under the framework of the International Rare Cancer Initiative. This protocol is for BALLAD BELGIUM, which is the component of GLOBAL BALLAD.

platelet count
cancer
adenocarcinoma
blood transfusion
adjuvant chemotherapy
  • 0 views
  • 16 Feb, 2024
  • 9 locations
Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis

Actinic cheilitis is a potentially malignant lesion on the lower lip, which can progress to more serious illnesses such as cancer if not treated. Usually treatment of this condition is only based on clinical appearance, but there is no established cure treatment.

  • 0 views
  • 16 Feb, 2024
  • 2 locations
PHP and Immunotherapy in Metastasized UM

Melanoma of the eye (ocular/uveal melanoma) is an uncommon type of cancer that is associated with a high mortality. It usually disseminates rapidly throughout the body, most commonly to the liver and lungs.

  • 0 views
  • 16 Feb, 2024
  • 1 location
Lung Irradiation for COVID-19 Pneumonia

The amount of radiation is much lower than what is typically used to treat other conditions such as cancer, although it is higher than the dose used for routine medical imaging.

favipiravir
aspirin
cancer
pneumonia
chloroquine
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

These T cells are involved in fighting infections and in some cases, can also kill cancer cells. The investigators will extract T cells from the participant's blood, modify the cells in a laboratory, and then return teh cells to the participant's body via intravenous (IV) injection.

burkitt's lymphoma
flow cytometry
hodgkin's disease
b-cell lymphoma
immunohistochemistry
  • 0 views
  • 16 Feb, 2024
  • 1 location
NoIAmNot Trial

Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …

  • 0 views
  • 21 Feb, 2023
enrolling Trial

Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …

  • 0 views
  • 22 Feb, 2023